Key result
Aspirin cessation resolves severe respiratory symptoms in suspected aspirin-exacerbated respiratory disease.
Why the study?
Aspirin-exacerbated respiratory disease creates a prescribing dilemma in patients with concomitant coronary artery disease, as aspirin protects the heart but may trigger bronchospasm, requiring close cooperation to select a safe antiplatelet regimen.
Case Report (n=1)
No
This case report highlights the importance of taking a structured aspirin and NSAID history at admission to guide antiplatelet therapy decisions in patients with comorbid asthma and coronary artery disease, avoiding premature discontinuation of aspirin based solely on unconfirmed suspicion of AERD.
Answers are grounded in this paper and cite their sources.
Supports clopidogrel continuation in suspected AERD; leaves open whether structured allergy histories improve CAD outcomes.
Introduction: Aspirin-exacerbated respiratory disease (AERD, also called aspirin-induced asthma or Samter's triad) is an asthma phenotype in which aspirin and other COX-1 inhibitors can trigger bronchospasm, usually alongside chronic rhinosinusitis with nasal polyps. It creates a real prescribing problem when the patient also has coronary artery disease, because the drug that protects the heart may be the one that provokes the airway. Choosing a safe antiplatelet drug, while keeping the asthma regimen safe too, calls for close cooperation between the treating team and the clinical pharmacist. Main symptoms and clinical findings: A 71-year-old woman with long-standing asthma, a previous episode of pulmonary infiltrates with eosinophilia (PIE), recurrent rhinitis and coronary artery disease came in with two to three days of worsening wheeze, chest tightness and increased sputum. She had bilateral wheeze but stable vital signs, with an oxygen saturation of 98% on room air. High-sensitivity troponin I was normal (1.9 pg/mL), and her renal and liver function were normal. Diagnoses, interventions and outcomes: The working diagnosis was an acute exacerbation of asthma with possible AERD. She was treated with nebulised levosalbutamol–ipratropium, formoterol–budesonide, tiotropium, intravenous hydrocortisone, etofylline/theophylline, montelukast–levocetirizine and antibiotics. Sinus CT showed no polyps and no aspirin reaction was documented, so the AERD label stayed presumptive. After cardiology review, aspirin was stopped on Day 4, while clopidogrel and rosuvastatin were continued. Her wheeze, breathlessness and sputum improved, and she went home on Day 6. Conclusion: When an older patient with asthma and coronary disease may have AERD, the aspirin question is a medicines problem as much as a diagnostic one. Here, a presumptive label made without nasal polyps or a documented aspirin reaction led to aspirin being stopped and clopidogrel continued. The case argues for a structured aspirin and NSAID history at admission, so that antiplatelet decisions rest on a recorded reaction and not on suspicion.
No takes yet. Share an insight, caveat, or question.
G et al. (2026) conducted a case report in Acute asthma exacerbation with suspected aspirin-exacerbated respiratory disease (AERD) and coronary artery disease (n=1). Aspirin discontinuation with continuation of clopidogrel and asthma pharmacotherapy was evaluated on Clinical improvement in wheeze, breathlessness, and sputum allowing hospital discharge. Stopping aspirin on Day 4 while continuing clopidogrel and bronchodilator/corticosteroid therapy improved respiratory symptoms in a 71-year-old woman with suspected AERD, enabling discharge on Day 6.
Synapse has enriched 10 related papers. Consider them for comparative context: